MIAMI (PRWEB) February 16, 2015 Global Stem Cells Group, Inc. announced an alliance with India-based stem cells company Advancells.com, to share protocols and expand GSCG operations in the India subcontinent with stem cell training and a new treatment center. Advancells, a pioneer stem cell company with some of the most advanced protocols in the world, focuses on therapeutic applications of regenerative medicine primarily used in stem cells generated from the patients own body. Advancells delivers technologies for safe and effective treatments using their flagship technologies including autologous stem cell therapy from bone marrow and adipose tissue to patients worldwide; Global Stem Cells Group will implement some Advancells technologies in the Regenestem Netowork of worldwide clinics. Since 2005, Advancells has safely treated thousands of patients for a range of diseases and medical conditions in its various clinics around the globe. Advancells is supported by physicians, stem cell experts and clinical research scientists to continually monitor and improve the effectiveness of its quality management system with excellence and innovation. "We are pleased to partner with Global Stem Cells Group, to combine our knowledge and expand our ability to bring stem cell medicine to patients worldwide, says Advancells CEO Vipul Jain. I am … Continue reading →

(MENAFN - ProactiveInvestors) () has been granted an ASX trading halt regarding the status of its Cymerus mesenchymal stem cell product manufacture. The halt will last until the earlier of the announcement being made or the start of trade on Thursday 19th February 2015. Its Cymerus technology enables large scale production of mesenchymal stem cells from a single one-time donor a pivotal requirement for pharmaceutical companies moving into stem cell medicine. Earlier this month it partner with the University of Western Australia to test its stem cells in lung fibrosis disease model. Proactive Investors Australia is the market leader in producing news articles and research reports on ASX Small and Mid-cap stocks with distribution in Australia UK North America and Hong Kong / China. See the article here: Cynata Therapeutics to provide status of stem cell product manufacturing technology … Continue reading →